Greg Licholai
How Is the Pharmaceutical Industry Responding to COVID-19?
As pharmaceutical companies work to develop potential vaccines and treatments for COVID-19, they are operating under extreme pressure—as well as the restrictions on movement and interaction that are affecting all of us.
Has Employment Become the Goal of the U.S. Healthcare System?
Dr. Greg Licholai writes that the complexity of the healthcare system has generated unexpected incentives—one of which is that we have come to rely on the industry for jobs.
Is CRISPR Worth the Risk?
Dr. Greg Licholai, a biotech entrepreneur and a lecturer at Yale SOM, explains the gene-editing technology’s potential and its dangers.
Three Questions: Dr. Greg Licholai on Biotech After Theranos
We asked Dr. Greg Licholai, a lecturer at Yale SOM and and a biotech entrepreneur, what other healthcare startups can learn from the Theranos debacle.
